Featuring an interview with Prof Martin Reck, including the following topics:

• Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
• Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
• Considerations with maintenance therapy for ES-SCLC (9:31)
• Considerations with immunotherapy for ES-SCLC (13:12)
• Curability of SCLC with systemic therapy (15:17)
• Data with chemoimmunotherapy for patients with poor performance status (25:55)
• Future developments in therapy for SCLC (30:11)
• Rapid fire: Small Cell 101 (35:45)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics:

• Introduction (0:00)
• Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52)
• Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16)
• Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O’Malley (1:00:31)

CME information and select publications